SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-009686
Filing Date
2022-05-12
Accepted
2022-05-12 16:20:55
Documents
71
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kzr-20220331.htm   iXBRL 10-Q 2302000
2 EX-31.1 kzr-ex31_1.htm EX-31.1 21095
3 EX-31.2 kzr-ex31_2.htm EX-31.2 21096
4 EX-32.1 kzr-ex32_1.htm EX-32.1 12629
5 GRAPHIC img38309705_0.jpg GRAPHIC 95598
  Complete submission text file 0000950170-22-009686.txt   8529553

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kzr-20220331.xsd EX-101.SCH 52965
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kzr-20220331_cal.xml EX-101.CAL 45359
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kzr-20220331_pre.xml EX-101.PRE 311787
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kzr-20220331_lab.xml EX-101.LAB 422969
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kzr-20220331_def.xml EX-101.DEF 164346
65 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20220331_htm.xml XML 1601321
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38542 | Film No.: 22918130
SIC: 2834 Pharmaceutical Preparations